Oncology Times - OncTimes Talk

Masood Moghul, MBBS, a urologist and Research Fellow at the Royal Marsden Hospital and Institute of Cancer Research in London shared findings from a study investigating a mobile, targeted, case-finding approach to prostate cancer detection with 3,379 patients.

Moghul told the 2025 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in San Francisco how the study addressed health inequalities and barr...

At the 2025 ASCO Genitourinary Cancers Symposium, researchers from Japan reported marked differences between the populations of several key microbial species in the gut microbiomes of patients with metastatic prostate cancer that distinguished them from those with non-metastatic disease. This was in the PROMISE-JAPAN study with 869 Japanese patients.

After talking about his group’s new data, lead researcher Koji Hatano...

A numerical formula called the absolute percentage pattern 4/5 (APP4) combining risk factors, including Gleason grade, PSA, and digital rectal examination, is being used to select patients whose intermediate risk prostate cancer can safely be followed with active surveillance.

A research study using APP4 was reported at the 2025 ASCO Genitourinary Cancers Symposium in San Francisco. First author Ruben Del Castillo, MD, a rad...

Masood Moghul, MBBS, a urologist and research fellow at the Royal Marsden Hospital and Institute of Cancer Research in London, UK, discussed his group’s findings from the Man Van study investigating a mobile, targeted, case-finding approach to prostate cancer detection with 3,379 patients conducted in Greater London.

Moghul told the 2025 ASCO Genitourinary Cancers Symposium in San Francisco how the study had addressed ...

In the third episode of A Deep Dive Into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we’re speaking with Dr. David O’Malley, and Bobbie R, an ovarian cancer patient. Dr. O’Malley will highlight how HRD testing empowers ovarian cancer patients to make more informed decisions with their doctors to help guide their treatment journey, and Bobbie will provide insight into her ex...

In the second episode of A Deep Dive into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we’re speaking with Dr. Erin Crane who will highlight how HRD testing provides helpful information to ovarian cancer patients.

Erin K. Crane, MD, MPH, is a gynecologic oncologist with Atrium Health Levine Cancer in Charlotte, North Carolina. A graduate of the SUNY Upstate Medical University in ...

In the first episode of A Deep Dive into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we’re speaking with Dr. Kathleen Moore about HRD testing in ovarian cancer and its clinical significance in helping aid precision medicine approaches.

Dr. Kathleen Moore is a Professor of Gynecologic Oncology at the University of Oklahoma Health Sciences Center, Associate Director of Clinical Re...

Although one in five colorectal cancers having microsatellite instability and expressing the Werner Helicase (WRN) gene could be treated with drugs that inhibit WRN, the effectiveness of such an approach has been limited by resistance. However, researchers identified the Cys727 mutation as being solely responsible for WRN inhibitor resistance. This potentially opens the door to using WRN inhibitors in the cancer clinic by inactivat...

A tumor-agnostic classifier and screening tool was announced at ESMO Congress 2024 in Barcelona. It was created to make it easier and quicker to develop new drugs that have specific molecular targets, and thus have potential anti-cancer efficacy irrespective of tumor type or location.

The ESMO Tumour-Agnostic Classifier and Screener was the result of work by a multidisciplinary team of international experts led by the ESMO Precis...

Findings from a study of patients receiving targeted therapy for their BRAFV600 mutation-positive advanced melanoma, suggest that switching early to immune checkpoint inhibition appeared to bring better rates of overall survival than saving immunotherapy for use as salvage treatment later on.

The ESMO 2024 Annual Congress heard from the randomized Phase II ImmunoCobiVem trial that a switch to immunotherapy after only 3 months trea...

A clinically meaningful benefit in overall survival was found in the second interim analysis of the randomized, double-blind, Phase III KEYNOTE-A18 study of immunotherapy together with concurrent chemoradiotherapy among 1,060 patients who had newly diagnosed, previously untreated high-risk locally advanced cervical cancer.

A multinational team of researchers, led from Italy, reported findings at the ESMO Congress 2024. There was a...

The prospect of markedly raising chemotherapy response rates and extending patient survival has been held out by scientists reporting a new AI-powered digital tool to optimize cancer management for individual patients.

The tool creates a “digital twin” for each patient that makes it possible to predict response to specific treatment regimens and confidently predict outcomes, according to findings from a study rep...

The prospect of a minimally toxic, chemotherapy-free cure for hepatoblastoma is held out by findings from a mouse model using the small-molecule drug WNTinib that inhibits the Wnt signaling pathway involved with cancer growth.

Lead author Ugnė Balaševičiūtė, a pre-doctoral researcher in Translational Research of the Hepatic Oncology Group led by Josep M. Llovet, Professor at the Institut D'Investigacions Biomediques A...

A chemotherapy-free combination of two anti-human epidermal growth factor receptor 2 (anti-HER2) agents brought clinically meaningful responses to patients with bile duct cancers testing positive for HER2 or with mutated HER2 in research from Japan reported at the EORTC-NCI-AACR 2024 Molecular Targets and Cancer Therapeutics Symposium held in Barcelona, Spain.

In the SGNTUC-019 Phase II basket study of 217 patients, who had ...

The fibroblast growth factor receptor-3 (FGFR-3) inhibitor TYRA-300 has been found safe with dose-dependent responses and disease control in the Phase I SURF301 trial. The study included 41 patients who had been heavily pre-treated for their advanced solid tumors with activating FGFR3 mutations/fusions, bringing the hope of avoiding toxicities from the use of non-specific pan-FGFR inhibition.

The findings were reported by Be...